Background-Cardiomyopathy is the leading cause of death in Duchenne muscular dystrophy (DMD). Standard cardiac biomarkers are poor indicators of DMD cardiovascular disease. Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) regulate collagen turnover. Given the cardiac fibrosis seen in DMD, we hypothesized that MMPs and TIMPs correlate with severity of DMD cardiomyopathy. Methods and Results-Prospectively enrolled DMD subjects (n=42) underwent cardiac MRI for function and late gadolinium enhancement (LGE), including LGE severity from 0 (no LGE) to 4 (severe). Serum from DMD and healthy male controls (n=15) analyzed for MMP 1, 2, 3, 7, 9, 10 and TIMPs 1-4. MMP1, MMP7, and MMP10 were higher in DMD than control (median 5080pg/ml vs. 2120pg/ml, p=0.007; 2170pg/ml vs. 1420pg/ml, p<0.001; 216pg/ml vs. 140pg/ml, p=0.040); TIMP4 was lower in DMD (124pg/ml vs. 263pg/ml, p=0.046). Within DMD, MMP7 correlated inversely with left ventricular ejection fraction (r=−0.40, p=0.012) and directly with
HGF may be a specific marker that distinguishes AL cardiac amyloidosis from other cardiomyopathies with similar clinical or morphologic characteristics. Further studies are necessary to determine whether HGF levels predict the likelihood of survival.
Retrospective studies suggest that chimeric antigen receptor T-cell (CAR T) therapy may lead to cardiac injury, but this has not been assessed systematically or prospectively. In this prospective study of 40 patients who received CAR T, we systematically measured high-sensitivity troponin T (hsTropT) and N-terminal pro-B natriuretic peptide (NTproBNP) at baseline and on day 1, days 7, and 21 after CAR T. Biomarker elevations with respect to timepoint and cytokine release syndrome (CRS) status were examined using repeated measure analysis of variance. hsTropT did not differ with time or with the presence of grade 2 CRS. Median hsTropT was 12.1 ng/L [interquartile range (IQR): 9.2, 20.1] at baseline, 13.1 ng/L (IQR: 9.6, 24.2) at day 1, 11.9 ng/L (IQR: 9.6, 18.0) at day 7, and 15.3 ng/L (10.8, 20.2) at day 21. In contrast, NTproBNP rose on day 1 (P Wilcox = 0.0002) and day 7 (P Wilcox = 2.7 ´ 10 −5 ), and the degree of elevation differed by the presence of grade 2 CRS (P interaction = 0.002). Median NTproBNP was 179 pg/mL (IQR: 116, 325) at baseline, 357 pg/mL (IQR: 98, 813) at day 1, 420 pg/mL (IQR: 239, 1242) at day 7, and 177 pg/mL (IQR: 80, 278) at day 21. In conclusion, hsTropT l did not differ across timepoints after CAR T therapy, but NTproBNP rose at day 7, the prognostic implications of which should be the target of future research, as the indications for this therapy expand.
Biomarkers are routinely used for noninvasive identification or monitoring of disease
processes in clinical practice, as well as surrogate end points for drug development.
There is a significant lack of data regarding biomarkers in children. An understanding of
biomarker levels in a healthy pediatric cohort is essential as more studies begin to apply
noninvasive biomarkers to pediatric populations. Brain-derived neurotrophic factor (BDNF)
functions in neuronal survival and plasticity and is associated with exercise capacity and
inflammatory disease processes. Osteopontin (OPN) plays a regulatory role in inflammation
and may be a clinically useful biomarker of cardiovascular disease processes, ventricular
remodeling, and skeletal muscle regeneration. This study describes our initial experience
with a cohort of healthy pediatric patients and seeks to provide normal values of BDNF and
OPN with correlation to age, gender, and cardiovascular and fitness measures. Serum BDNF
and plasma OPN were measured using enzyme-linked immunosorbent assay in 33 healthy
pediatric subjects. Subjects underwent complete cardiac evaluation, including
echocardiography, exercise stress testing, and health risk assessment. The 5th–95th
percentile was 5.63–37.86 ng/ml for serum BDNF and 4.9–164.9 ng/ml for plasma OPN. Plasma
OPN correlated with number of days of exercise per week (r = 0.46,
p = 0.008). No other correlations were significant. This study provides
the initial data on serum BDNF and plasma OPN in children and begins to explore the
relationships of BDNF and OPN to cardiovascular health and fitness in the pediatric
population.
The purpose of this study was to assess insulin-stimulated gene expression in canine skeletal muscle with a particular focus on NPPC, the gene that encodes C-type natriuretic peptide, a key hormonal regulator of cardiometabolic function. Four conscious canines underwent hyperinsulinemic, euglycemic clamp studies. Skeletal muscle biopsy and arterial plasma samples were collected under basal and insulin-stimulated conditions. Bulk RNA sequencing of muscle tissue was performed to identify differentially expressed genes between these two steady-state conditions. Our results showed that NPPC was the most highly expressed gene in skeletal muscle in response to insulin infusion, rising fourfold between basal and insulin-stimulated conditions. In support of our RNA-sequencing data, we found that raising the plasma insulin concentration 15-fold above basal elicited a 2-fold (p = 0.0001) increase in arterial plasma concentrations of N-terminal prohormone C-type natriuretic peptide. Our data suggest insulin may play a role in stimulating secretion of C-type natriuretic peptide by skeletal muscle. In this context, C-type natriuretic peptide may act in a paracrine manner to facilitate muscle-vascular bed crosstalk and potentiate insulin-mediated vasodilation. This could serve to enhance insulin and glucose delivery, particularly in the postprandial absorptive state.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.